The PBM Rebate Problem:
Where Your Pharmacy Dollars Are Actually Going

Every year, American employers spend hundreds of billions of dollars on prescription drugs. And every year, a meaningful portion of that spend quietly disappears — not into drug manufacturers' pockets, and not into your employees' hands, but into the margin structures of Pharmacy Benefit Managers. PBMs are the most profitable and least understood players in the U.S. healthcare system. This article is about how they make money at your expense — and what you can do about it.

What a PBM actually does

A Pharmacy Benefit Manager is the administrative middleman between your health plan and the network of pharmacies your employees use. On paper, their job is straightforward: negotiate drug prices with manufacturers and pharmacies, manage your formulary, and process claims. The theory is that their purchasing power — aggregated across millions of covered lives — produces lower drug costs that flow through to employers and plan members.

The reality is considerably more complicated. The three largest PBMs — CVS Caremark, Express Scripts, and OptumRx — now control approximately 80% of the U.S. market. Their scale, combined with vertical integration into retail pharmacy chains, specialty pharmacies, and even insurance carriers, has given them extraordinary leverage. And they've used that leverage not primarily to reduce drug costs, but to build several overlapping profit mechanisms that operate largely invisible to the employers paying the bills.

Mechanism #1: Spread pricing

Spread pricing is the most direct way PBMs extract margin from your plan. Here's how it works: when your employee fills a prescription, the PBM pays the pharmacy one amount for the drug, and bills your plan a different — higher — amount. The difference is the spread, and the PBM keeps it.

On brand-name drugs, spreads are typically modest — the manufacturer pricing and wholesaler structures leave limited room. But on generic drugs, spreads can be extraordinary. A generic that costs the pharmacy $3 to dispense might be reimbursed at $4 by the PBM, while the PBM bills your plan $18. The PBM pockets $14 on a single $3 transaction, and your plan has no visibility into any of it.

Multiply this across thousands of generic fills per year, and the scale becomes significant. For a 300-employee employer, spread pricing on generics alone can represent $75,000–$150,000 in annual costs that appear nowhere in your benefits reporting — because PBMs aren't required to disclose it, and most don't.

Mechanism #2: Rebate retention

Drug manufacturers pay PBMs substantial rebates — essentially volume incentives — to secure favorable positioning on the PBM's formulary. A manufacturer might pay a 25% rebate on a brand-name drug to ensure it's listed as "preferred" on the formulary, meaning lower member cost-sharing and higher utilization. These rebates represent hundreds of billions of dollars flowing annually from manufacturers to PBMs.

The question is: where do those rebates go? In a rebate-sharing arrangement, the PBM returns some portion of the rebates to the employer — reducing net pharmacy cost. In a rebate retention arrangement — which is the default in most bundled carrier contracts — the PBM keeps the rebates entirely, supplementing spread pricing income with what amounts to a second hidden profit stream.

The perverse result of rebate retention is that PBMs are financially incentivized to prefer high-rebate brand-name drugs over lower-cost generics or biosimilars. A biosimilar that would cost your plan 40% less than the reference biologic may generate no rebate at all. The branded drug generates a significant rebate — which the PBM keeps. The formulary is designed around PBM economics, not plan economics.

Mechanism #3: Specialty pharmacy channel control

Specialty drugs — biologics, oncology agents, immunologics — now account for roughly 50% of pharmacy spend for a typical employer plan, despite representing fewer than 5% of prescriptions. These are the highest-cost, highest-margin products in the system, and PBMs have worked systematically to ensure that specialty fills route through their own affiliated specialty pharmacies rather than independent competitors.

This matters because specialty pharmacy margins are substantial. When a PBM-owned specialty pharmacy dispenses a $15,000 biologic injection, the margin isn't just the spread between acquisition cost and plan reimbursement — it includes inventory financing, manufacturer rebates, and dispensing fees. For a PBM that processes millions of specialty claims annually, this is an enormous profit center hidden inside your pharmacy benefit.

What the pass-through model actually means

The alternative to all of this is a transparent, pass-through PBM arrangement. In a pass-through model, the PBM's compensation is explicit and fixed: a flat administrative fee per member per month, fully disclosed upfront. The PBM passes through 100% of drug acquisition costs — exactly what the pharmacy was paid — and passes through 100% of rebates to the plan. No spread. No retained rebates. No hidden specialty margin.

Pass-through arrangements are essentially only available to self-funded employers, who have the contractual flexibility to negotiate directly with PBMs. Fully insured employers are locked into whatever pharmacy arrangement their carrier has negotiated — and carriers typically have their own PBM relationships structured around profitability, not transparency.

For a 300-employee employer spending $500,000 annually on pharmacy, moving to a pass-through PBM typically produces $80,000–$150,000 in year-one savings. The spread disappears. The rebates flow back to the plan. The specialty channel is competed rather than captive. That is a structural cost reduction that compounds every year.

How to assess your current situation

If you're currently fully insured, start by requesting your pharmacy claims data from your carrier or broker. Under ERISA, you have the right to this information. What you're looking for:

• Total pharmacy spend by drug category (generic, brand, specialty)
• Rebate amounts received by the plan (if any are passed through)
• Effective cost per claim vs. AWP (average wholesale price)
• Specialty pharmacy channel utilization

If your carrier or broker can't produce this data — or produces a report that shows only total spend without unit economics — that itself tells you something. Transparency starts with data access. If you don't have the data, you can't know what you're paying.

If you do have the data, benchmarking it against independent market norms will quickly reveal whether your plan is being priced at market or above it. In our experience, the majority of fully insured employers we evaluate have pharmacy economics that are meaningfully worse than what a transparent PBM arrangement would produce.